Loading company…
RocRock Biotechnology develops engineered macrophage technologies and drugs for solid tumors.
RocRock Biotechnology is based in Suzhou, China, and develops macrophage drugs for solid tumors. Its platforms support CAR-M preparation, macrophage activation, delivery of macromolecules, and subtype and target databases; the company identifies breast, lung, and liver cancers among potential applications. It has branches in Shenzhen and Berlin and partnerships with SYPM and Peking Union Medical College Hospital. In November 2025, it raised CNY 50 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in